Review
Biochemistry & Molecular Biology
Francesca Sanguedolce, Magda Zanelli, Andrea Palicelli, Alessandra Bisagni, Maurizio Zizzo, Stefano Ascani, Maria Carmela Pedicillo, Angelo Cormio, Ugo Giovanni Falagario, Giuseppe Carrieri, Luigi Cormio
Summary: Bladder cancer is a heterogeneous disease with molecular, morphological, and clinical variations. HER2 is an oncogene involved in the development of bladder cancer. Assessing HER2 overexpression through immunohistochemistry can be useful in correctly identifying different types of bladder lesions, providing prognostic information, and improving BC molecular subtyping. Additionally, HER2 has potential as a therapeutic target in the development of novel target therapies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Lan Shu, Yiwei Tong, Zhuoxuan Li, Xiaosong Chen, Kunwei Shen
Summary: HER2 1+ cases of breast cancer are similar to HER2 0 cases in terms of clinicopathological features and mRNA expression, but different from HER2 2+/FISH- cases. There is poor concordance between IHC/FISH and qRT-PCR for HER2-negative tumors. The current definition of HER2-low expression with the lower boundary of HER2 IHC 1+ may be inaccurate.
Review
Oncology
Joohyun Hong, Yeon Hee Park
Summary: Significant progress has been made in the treatment of HER2-positive breast cancer, especially with the development of targeted therapies. Different treatment approaches are applied based on the risk level and presence of residual disease, including adjuvant trastuzumab, pertuzumab, paclitaxel, and other drugs. Ongoing trials are exploring the combination of novel agents and de-escalation of treatment in the neoadjuvant setting, aiming to achieve better outcomes.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2022)
Review
Pharmacology & Pharmacy
Chao Tang, Heng Liu, Yanpeng Fan, Jiahao He, Fuqiu Li, Jin Wang, Yuchuan Hou
Summary: Bladder cancer is commonly treated with transurethral resection followed by intravesical chemotherapy, but conventional methods lack selectivity and efficiency. Nanomedicines offer targeted drug delivery with improved efficacy and precision, overcoming the challenges of conventional treatments.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Pharmacology & Pharmacy
Adlina Roslan, Nurshahira Sulaiman, Khairul Asri Mohd Ghani, Armania Nurdin
Summary: This review discusses the studies on membrane proteins as potential biomarkers for personalized medicine, describing their types and significant functions as potential biomarkers for future medicine.
Article
Nanoscience & Nanotechnology
Lingzhou Zhao, Jiali Gong, Qinli Qi, Changcun Liu, Hongxing Su, Yan Xing, Jinhua Zhao
Summary: The unique structure of nanobodies is advantageous for the development of radiopharmaceuticals for nuclear medicine. In this study, a 131I-labeled anti-HER2 nanobody was generated and evaluated as a targeted radionuclide therapy agent for HER2-positive breast cancer. The results showed that 131I-NM-02 had satisfactory radiochemical purity and stability, and demonstrated good therapeutic potential and organ compatibility in HER2-positive tumors.
INTERNATIONAL JOURNAL OF NANOMEDICINE
(2023)
Article
Cell Biology
Hongbing Gu, Chaozhao Liang
Summary: By studying the genetic characteristics and clinical features of bladder cancer patients, we have established a prognostic signature to predict patients' prognosis and response to targeted therapy. This signature was validated in different cohorts and showed independent predictive ability. We also identified potential targeted therapy options to meet the needs of patients with different risk scores.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Review
Oncology
Ali Abdulnabi Suwaidan, David K. Lau, Ian Chau
Summary: This article provides an overview of the clinicopathological features of HER2 amplification and mutations in metastatic colorectal cancer (mCRC), and its role as a biomarker of anti-EGFR resistance. The review also discusses the preclinical, clinical, and translational studies investigating the use of HER2 targeted therapies and future research.
CANCER TREATMENT REVIEWS
(2022)
Article
Oncology
Bin Xu, Jianguo Shen, Jun Shen, Linbo Wang
Summary: This study investigated the impact of HER2-low expression on survival outcomes in patients with HER2-negative early breast cancer. The results showed that HER2-low was associated with improved overall survival in patients with HR-negative disease, but no significant association was found in patients with HR-positive disease.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Medicine, General & Internal
Shin Ariga
Summary: Human epidermal growth factor receptor 2 (HER2) is a receptor tyrosine kinase that is overexpressed in 20% of gastric or gastroesophageal junction cancers. While effective in breast cancer, the use of anti-HER2 agents in gastric cancer has not shown survival benefits compared to standard therapies due to inherent differences in tumor biology. However, the development of a novel anti-HER2 agent, trastuzumab deruxtecan, offers promising future prospects for HER2-targeted therapy in gastric cancer.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Oncology
Junsha An, Cheng Peng, Xiaofang Xie, Fu Peng
Summary: This article describes potential targets for the treatment of breast cancer, including the PI3K/AKT signaling pathway, DNA damage response, angiogenesis, cell cycle, and breast cancer stem cells, and explores possible treatments for HER2-negative breast cancer.
FRONTIERS IN ONCOLOGY
(2022)
Article
Cell Biology
Nada Albarakati, Alaa Al-Shareeda, Majed Ramadan, Batla Al-Sowayan, Ola Negm, Taoufik Nedjadi
Summary: This study investigated the interaction between HER2 and ATM and their impact on patient survival and cancer aggressiveness in bladder cancer. The findings suggest that low ATM and high HER2 levels are significantly associated with poor clinicopathological variables and serve as powerful prognostic indicators for overall survival and disease-free survival.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
(2022)
Review
Oncology
Agampodi Danushi M. Gunasekara, Thunyarat Anothaisintawee, Sitaporn Youngkong, Nguyen T. Ha, Gareth J. McKay, John Attia, Ammarin Thakkinstian
Summary: This study aimed to identify the neoadjuvant anti-HER2 therapy with the best balance between efficacy and safety. The findings suggest that trastuzumab emtansine + pertuzumab + chemotherapy showed a high pathologic complete response with a low risk of adverse events, while the pertuzumab + trastuzumab + chemotherapy regimen had the highest disease-free survival. However, further trials are needed to confirm these findings, particularly for neoadjuvant regimens with trastuzumab emtansine.
Article
Pharmacology & Pharmacy
Victoria O. Shipunova, Mariia M. Belova, Polina A. Kotelnikova, Olga N. Shilova, Aziz B. Mirkasymov, Natalia Danilova, Elena N. Komedchikova, Rachela Popovtzer, Sergey M. Deyev, Maxim P. Nikitin
Summary: The study presents the promising use of silver nanoparticles with localized surface plasmon resonance (LSPR) phenomenon for targeted photothermal cancer therapy. These 35 nm HER2-targeted Ag NPs were synthesized using an aqueous extract of Lavandula angustifolia Mill, and demonstrated effective tumor treatment through hyperthermia after light irradiation. The Ag NPs were conjugated with affibody Z(HER2:342) polypeptide to target HER2-overexpressing cells, showing successful binding and internalization. Cytotoxicity assays showed effective cell death through reactive oxygen species production, and in vivo experiments resulted in complete tumor regression and prevention of metastasis.
Article
Medicine, General & Internal
Hai-Long Chen, Qiang Chen, Yong-Chuan Deng
Summary: This study evaluated the impact of HER2 immunohistochemistry (IHC) score on pathologic complete response (pCR) to neoadjuvant anti-HER2 therapy in early breast cancer patients. Patients with HER2 IHC 3+ tumors had a higher pCR rate compared to those with HER2 IHC 2+/FISH-positive tumors. The addition of pertuzumab to neoadjuvant treatment improved pCR rates, particularly in HER2 IHC 3+ tumors.
